News | August 01, 2024
Strides Pharma posts Q1 FY25 PAT at Rs. 68.3 Cr
The revenue for the Q1FY25 came in at Rs 1,085.7 crore, up 16.6 per cent YoY
The revenue for the Q1FY25 came in at Rs 1,085.7 crore, up 16.6 per cent YoY
AMP-6 & AMP-8 are special purpose entities formed for purpose of setting up captive solar power projects in Karnataka
Trinity has availed credit facility from Investec for Business for their working capital requirements of Rs. 31.5 crore
Strides Pharma Science Limited to acquire 100% in Strides Pharma Services Pvt Ltd.
The National Institute of Pharmacy and Nutrition, Hungary has issued 'Certificate of GMP Compliance of Manufacturer' for IOL Chemicals and Pharmaceuticals Limited's products.
The balance of AUD 94 Million was a deferred consideration backed by a secured interest-bearing instrument
The company has posted net loss of Rs. 460.21 crores for the Financial Year ended March 31, 2022.
They will commercialize molnupiravir in the international markets
Strides Pharma Science has reported consolidated financial results for the period ended September 30, 2021
The company expects revenue growth of 10-15 per cent in the US
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
